Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | PAM | P19021 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1870 | 1.00 | IDO1 (0.52) | IDO1PAMMAOBHTR2APTGER4 | |
| SCHEMBL4863423 | 0.80 | IDO1 (0.58) | IDO1PAMMAOBHTR2ANPC1 | |
| SCHEMBL9777486 | 0.80 | IDO1 (0.58) | IDO1PAMMAOBHTR2ANPC1 | |
| SCHEMBL7939387 | 0.78 | IDO1 (0.56) | IDO1PAMMAOBHTR2ASIGMAR1 | |
| SCHEMBL10430031 | 0.78 | IDO1 (0.56) | IDO1PAMMAOBHTR2ASIGMAR1 | |
| SCHEMBL7568412 | 0.78 | IDO1 (0.56) | IDO1PAMMAOBHTR2ASIGMAR1 | |
| SCHEMBL4256257 | 0.77 | MAOB (0.67) | IDO1PAMMAOBHTR2APTGER4 | |
| SCHEMBL1892917 | 0.77 | MAOB (0.67) | IDO1PAMMAOBHTR2APTGER4 | |
| SCHEMBL163963 | 0.77 | MAOB (0.67) | IDO1PAMMAOBHTR2APTGER4 | |
| SCHEMBL19284235 | 0.76 | IDO1 (0.54) | IDO1PAMMAOBHTR2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376428-A2 | NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN | Universitätsklinikum Münster (DE) | 2011-10-19 | — | — | EP | claimed |
| US-20110245335-A1 | NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN | UNIVERSITAETSKLINIKUM MUENSTER (DE) | 2011-10-06 | — | — | US | claimed |
| WO-2010066909-A2 | NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN | Universitätsklinikum Münster (DE) | 2010-06-17 | — | — | WO | claimed |
| EP-1537853-A1 | Use of a composition comprising a compound comprising a lacton ring and/or a corresponding coloring agent with an open ring for dyeing keratinuous fibers | L'OREAL (FR) | 2005-06-08 | — | — | EP | claimed |
| US-4010191-A | Acyl derivatives of substituted bis-arylalkylamino compounds | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1977-03-01 | — | — | US | claimed |
| EP-2376428-A2 | NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN | Universitätsklinikum Münster (DE) | 2011-10-19 | — | — | EP | disclosed |
| US-20110245335-A1 | NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN | UNIVERSITAETSKLINIKUM MUENSTER (DE) | 2011-10-06 | — | — | US | disclosed |
| WO-2010066909-A2 | NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN | Universitätsklinikum Münster (DE) | 2010-06-17 | — | — | WO | disclosed |
| EP-1746880-A1 | QUINOXALIN-2-ONE DERIVATIVES CROP PROTECTION AGENTS COMPRISING THE SAME AND METHOD FOR PRODUCTION AND USE THEROF | Bayer CropScience GmbH (DE) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005112630-A1 | QUINOXALIN-2-ONE DERIVATIVES CROP PROTECTION AGENTS COMPRISING THE SAME AND METHOD FOR PRODUCTION AND USE THEROF | BAYER CROPSCIENCE GMBH (DE) | 2005-12-01 | — | — | WO | disclosed |
| EP-1537853-A1 | Use of a composition comprising a compound comprising a lacton ring and/or a corresponding coloring agent with an open ring for dyeing keratinuous fibers | L'OREAL (FR) | 2005-06-08 | — | — | EP | disclosed |
| EP-0711760-B1 | METHOD OF ALKYLATING TRIAZINE DERIVATIVE | NISSAN CHEMICAL IND LTD (JP) | 2002-05-15 | — | — | EP | disclosed |
| US-5965592-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0882720-A1 | METHODS FOR MODIFYING 1,3,5-TRIAZINE DERIVATIVES | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1998-12-09 | — | — | EP | disclosed |
| US-5792867-A | Method of alkylating of triazine derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-08-11 | — | — | US | disclosed |
| EP-0760369-A1 | PROCESS FOR ALKYLATING TRIAZINE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-03-05 | — | — | EP | disclosed |
| EP-0711760-A1 | METHOD OF ALKYLATING TRIAZINE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1996-05-15 | — | — | EP | disclosed |
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245335-A1 | NEW INHIBITORS FOR TREATING DISEASES ASSOCIATED WITH AN EXCESS TRANSPORT OF HYALURONAN | SLC10A1, ABCB11, HEXD | IDO1 1149/4885PAM 4025/4885MAOB 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.